

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 10 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 09/19-21, 24-25/2018
	FEI NUMBER 3004610520

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: William S McFarland, Owner

FIRM NAME Loop Plaza Pharmacy Company DBA Loop Compounding Phar	STREET ADDRESS 72 6th Ave
CITY, STATE AND ZIP CODE Saint Albans, WV 25177-2769	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile and Non Sterile Drug Products

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

OBSERVATION 1

The ISO 5 classified area is located within a non-classified room (segregated production area).
Specifically, there is no assurance the cleanroom surrounding the ISO 5 laminar air flow hood is operating within classified conditions. The last certification was completed on February 22 2018 and was due for re-certification in (b) (4). The firm has produced approximately (b) (4) products on a (b) (4) in the cleanroom since September.

OBSERVATION 2

Non-sterilized or non-depyrogenated tools or temporary containers were used in sterile drug production
Specifically, there is no assurance that the (b) (4) used to store bulk solution can maintain sterility through the (b) (4). The firm produced bulk solution vials of Bupivacaine HCl 40mg/ml lot 09202018@9, Hydromorphone 100mg/ml lot 08092018@54, Morphine 100mg/ml lot 08272018@66, Clonidine HCl 2000 mcg/ml lot 08212018@27, and Hydromorphone 100mg/ml lot 08092018@54. These products are stored (b) (4) and are used for patient specific prescriptions, during which the (b) (4). The Bupivacaine HCl (lot 09202018@9) and Hydromorphone (lot 08092018@54) were used in the production of prescription compound Hydromorphone HCl: Bupivacaine HCl 280 mg: 410 mg (b) (4) with prescription number (b) (6)

Add Continuation Page

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Melissa T Roy, CSO	DATE ISSUED 09/25/2018
--------------------------	--	--	---------------------------

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 6000 Metro Drive, Suite 10 Baltimore, MD 21215 (410) 779-5455 Fax: (410) 779-5707 Industry Information: www.fda.gov/oc/industry		DATE(S) OF INSPECTION 09/19-21, 24-25/2018 FEI NUMBER 3004610520
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: William S McFarland, Owner		
FIRM NAME Loop Plaza Pharmacy Company DBA Loop Compounding Phar	STREET ADDRESS 72 6th Ave	
CITY, STATE AND ZIP CODE Saint Albans, WV 25177-2769	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile and Non Sterile Drug Products	

OBSERVATION 3

ISO-5 classified areas were not certified under dynamic conditions. Specifically, unidirectional airflow was not verified under operational conditions.

Specifically, no dynamic smoke studies were performed during the last cleanroom certification on February 22, 2018 to demonstrate unidirectional airflow is maintained in the firm's (b) (4) ISO 5 hoods used to produce aseptically filled products. This is a repeat observation from the previous inspection.

OBSERVATION 4

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically, media fills performed by the operators do not simulate the aseptic filling process under normal operating conditions. The operator can fill up to (b) (4) of a drug product in (b) (4), however the current media fill procedure only has the operator (b) (4)

Add Continuation Page

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Melissa T Roy, CSO	DATE ISSUED 09/25/2018
-----------------------------------	--	--	---------------------------